PA
THRM icon

PharVision Advisers’s Gentherm THRM Stock Holding History

PharVision Advisers’s Portfolio THRM Stock Details THRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,430
Closed -$297K – 506
2024
Q4 		$297K Buy
+7,430
New +$311K 0.25% 159

Other funds holding THRM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

PharVision Advisers's THRM Position: Q1 2025 in Review

PharVision Advisers sold out of Gentherm (THRM) in Q1 2025, closing a stake of 7,430 shares — an estimated $297K sold.

PharVision Advisers first reported a position in THRM in Q4 2024 and held it in 1 quarter. The position peaked at $297K in Q4 2024. 219 funds tracked by Wall St. Rank hold THRM as of Q1 2025.

  • PharVision Advisers reported no remaining Gentherm position as of Q1 2025 after selling out during the quarter.
  • PharVision Advisers sold 7,430 Gentherm shares in Q1 2025, an estimated $297K.
  • PharVision Advisers first reported a position in Gentherm in Q4 2024 and held it in 1 quarter.
  • PharVision Advisers's Gentherm position peaked at $297K in Q4 2024.
  • 219 funds tracked by Wall St. Rank held Gentherm as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.